New vaccine candidate receives IND clearance in China and Australia.
- Delonix Bioworks announces IND clearance for a new MenB vaccine
- DX-104 is an engineered OMV vaccine candidate
- Approval received in China and Australia
Delonix Bioworks has announced that it has received Investigational New Drug (IND) clearance for DX-104, a novel engineered vaccine candidate targeting Meningococcal B (MenB). This development allows the company to conduct clinical trials in China and Australia. The MenB OMV vaccine aims to provide a new option in meningococcal prevention.
The IND clearance is significant as it permits Delonix Bioworks to begin testing DX-104 in human subjects, contributing to the potential expansion of vaccine options for MenB. This vaccine, engineered with outer membrane vesicles (OMVs), represents an innovative approach in combating this serious bacterial infection. The company aims to initiate clinical trials in these countries as part of its development strategy.
Delonix Bioworks focuses on developing advanced vaccine candidates, and the clearance from regulatory authorities in China and Australia marks a crucial step forward for the DX-104 vaccine candidate. With MenB being a major public health concern, this novel approach may help improve existing vaccination strategies.
